Company / Operating Income
Ligand Pharmaceuticals, Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$41.0M
FY2025
5-year range
-$22.6M / $103.9M
FY2021-FY2025
Trend
+281.4%
vs FY2024
Sector context
#47 of 204
Health Care
What the data says
Operating Income changed +281% YoY in FY2025, a notable deviation from the 9-year average annual change of +95%.
Based on SEC 10-K filings.
$41M in FY2025 with a 5-year CAGR of +1.8%. Top quartile in the Health Care sector.
Improved from $12M to $41M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- +138.1%
- 5-Year CAGR
- +1.8%
- 10-Year CAGR
- -
Sector benchmark
Top 23% in Health CareTop 23% of 204This company $41.0M Sector average $107.7M
▼
-61.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +1.8%, indicating consistent growth.
- In FY2025, operating income increased 281.4% year-over-year.
- Ranks #47 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2019.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $41.0M | +281.4% |
| FY2024 | -$22.6M | -289.3% |
| FY2023 | $11.9M | +293.2% |
| FY2022 | $3.0M | -97.1% |
| FY2021 | $103.9M | +176.9% |
| FY2020 | $37.5M | -95.4% |
| FY2019 | $807.1M | +392.9% |
| FY2018 | $163.7M | +140.5% |
| FY2017 | $68.1M | +55.1% |
| FY2016 | $43.9M | +60.6% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026